REPH: Recro Pharma, Inc. is a Sell
The current rating for REPH is 49, which is
its historic median rating of 50. This indicates higher risk than normal.
The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.